|
Aug 14
|
Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
|
|
Jun 24
|
Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program
|
|
Jun 13
|
Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
|
|
Dec 27
|
Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
|
|
Dec 21
|
Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
|
|
Nov 8
|
Matinas BioPharma Holdings Inc (MTNB) Reports Q3 2023 Financial Results and Business Progress
|
|
Nov 8
|
Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update
|
|
Nov 7
|
Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model
|
|
Aug 22
|
Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases
|